234 related articles for article (PubMed ID: 33516629)
21. Targeting ferroptosis in pancreatic cancer: a double-edged sword.
Chen X; Kang R; Kroemer G; Tang D
Trends Cancer; 2021 Oct; 7(10):891-901. PubMed ID: 34023326
[TBL] [Abstract][Full Text] [Related]
22. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
[TBL] [Abstract][Full Text] [Related]
23. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
24. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
25. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
26. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer.
Modi S; Kir D; Banerjee S; Saluja A
J Cell Biochem; 2016 Feb; 117(2):279-88. PubMed ID: 26206252
[TBL] [Abstract][Full Text] [Related]
27. Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models.
Su L; Chen Y; Huang C; Wu S; Wang X; Zhao X; Xu Q; Sun R; Kong X; Jiang X; Qiu X; Huang X; Wang M; Wong PP
Sci Transl Med; 2023 Jan; 15(678):eabl7895. PubMed ID: 36630483
[TBL] [Abstract][Full Text] [Related]
28. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
29. Selective induction of apoptosis: promising therapy in pancreatic cancer.
Liu Z; Li D; Zheng X; Wang E; Wang J
Curr Pharm Des; 2013; 19(12):2259-68. PubMed ID: 23082976
[TBL] [Abstract][Full Text] [Related]
30. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
31. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
32. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
[TBL] [Abstract][Full Text] [Related]
33. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
34. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
Lipner MB; Peng XL; Jin C; Xu Y; Gao Y; East MP; Rashid NU; Moffitt RA; Herrera Loeza SG; Morrison AB; Golitz BT; Vaziri C; Graves LM; Johnson GL; Yeh JJ
JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32213714
[TBL] [Abstract][Full Text] [Related]
35. Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.
Xu C; Wang Y; Tu Q; Zhang Z; Chen M; Mwangi J; Li Y; Jin Y; Zhao X; Lai R
Oncogene; 2019 Mar; 38(11):1832-1844. PubMed ID: 30356139
[TBL] [Abstract][Full Text] [Related]
36. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
37. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.
Delitto D; Vertes-George E; Hughes SJ; Behrns KE; Trevino JG
World J Gastroenterol; 2014 Jul; 20(26):8458-70. PubMed ID: 25024602
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
39. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
40. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
Bisht S; Brossart P; Feldmann G
Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
